Eric Baudin

Eric Baudin is a leading endocrine oncologist at Gustave Roussy with expertise spanning adrenocortical carcinoma, neuroendocrine tumors, and hereditary endocrine syndromes including MEN1. He has conducted key studies on pembrolizumab in refractory ACC and contributed to understanding the immunotherapy landscape of adrenal tumors. He also leads clinical research on peptide receptor radionuclide therapy (PRRT) for somatostatin receptor-positive neuroendocrine tumors and is an author of French and European guidelines on rare endocrine malignancies.